Zenas BioPharma (NASDAQ:ZBIO) Issues Earnings Results

Zenas BioPharma (NASDAQ:ZBIO) announced its quarterly earnings results on Wednesday. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($1.37) by ($0.09), FiscalAI reports. During the same quarter in the prior year, the business posted ($0.80) earnings per share.

Zenas BioPharma Stock Performance

Shares of ZBIO traded up $0.77 during mid-day trading on Wednesday, hitting $19.93. The company’s stock had a trading volume of 516,448 shares, compared to its average volume of 863,871. The stock’s 50-day moving average is $21.48 and its two-hundred day moving average is $26.84. The firm has a market capitalization of $1.14 billion, a PE ratio of -2.55 and a beta of -0.61. The company has a debt-to-equity ratio of 0.32, a quick ratio of 5.61 and a current ratio of 5.61. Zenas BioPharma has a one year low of $8.53 and a one year high of $44.60.

Analysts Set New Price Targets

Several analysts recently issued reports on ZBIO shares. Guggenheim upped their price objective on shares of Zenas BioPharma from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 16th. Morgan Stanley lifted their target price on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 17th. Citigroup dropped their target price on shares of Zenas BioPharma from $43.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, March 17th. Wall Street Zen downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Saturday, March 21st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Zenas BioPharma in a report on Friday, March 27th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $44.14.

Insider Activity at Zenas BioPharma

In related news, Director Patricia L. Allen purchased 15,700 shares of the firm’s stock in a transaction on Thursday, February 12th. The shares were bought at an average cost of $24.85 per share, for a total transaction of $390,145.00. Following the transaction, the director directly owned 15,700 shares of the company’s stock, valued at approximately $390,145. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Fairmount Funds Management Llc acquired 150,000 shares of the company’s stock in a transaction dated Tuesday, March 31st. The shares were bought at an average price of $20.00 per share, for a total transaction of $3,000,000.00. Following the acquisition, the director owned 2,359,025 shares in the company, valued at approximately $47,180,500. This trade represents a 6.79% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 233,628 shares of company stock valued at $4,637,200 in the last 90 days. 22.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Zenas BioPharma

Several hedge funds have recently made changes to their positions in the stock. SR One Capital Management LP increased its stake in Zenas BioPharma by 2.6% during the fourth quarter. SR One Capital Management LP now owns 5,037,854 shares of the company’s stock valued at $182,924,000 after acquiring an additional 126,315 shares during the period. NEA Management Company LLC increased its stake in Zenas BioPharma by 28.9% during the fourth quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after acquiring an additional 789,500 shares during the period. Federated Hermes Inc. increased its stake in Zenas BioPharma by 45.9% during the fourth quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after acquiring an additional 853,740 shares during the period. Vanguard Group Inc. increased its stake in Zenas BioPharma by 17.2% during the third quarter. Vanguard Group Inc. now owns 1,162,758 shares of the company’s stock valued at $25,813,000 after acquiring an additional 170,546 shares during the period. Finally, Geode Capital Management LLC increased its stake in Zenas BioPharma by 25.2% during the fourth quarter. Geode Capital Management LLC now owns 588,393 shares of the company’s stock valued at $21,371,000 after acquiring an additional 118,358 shares during the period.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.